Form 4: Aligos Therapeutics Director Peter Hirth Acquires 60,000 Stock Options

Director Peter Hirth acquired 60,000 stock options in Aligos Therapeutics, Inc. on June 27, 2024.

Summary

• Peter Hirth, a director of Aligos Therapeutics, Inc., acquired 60,000 stock options on June 27, 2024.
• The exercise price of the stock options is $0.38.
• The options vest on the earlier of the first anniversary of the grant date or immediately prior to the annual meeting in 2025, subject to continuous service.
• The expiration date for the options is June 27, 2034.
• Following the transaction, Hirth directly owns 60,000 derivative securities.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock option grants, and doesn't inherently indicate positive or negative sentiment. It's a neutral event.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the transactions of company directors and officers.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates